HealthcareServices

Major Depressive Disorder Market Forecast 2026–2035: How to Leverage Market Growth

February 26, 2026February 26, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the major depressive disorder market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Major Depressive Disorder Market expected to reach by 2030?

The major depressive disorder market size has shown consistent expansion in recent years. This market is anticipated to increase from $6.26 billion in 2025 to $6.44 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 2.9%. The historical growth of the market is primarily a result of the rising prevalence of depressive disorders, increasing societal recognition of mental health issues, enhanced availability of antidepressant medications, the expansion of psychiatric care facilities, and refined diagnostic protocols for mood disorders.

The major depressive disorder market size is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach a valuation of $7.49 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 3.9%. Several factors are expected to fuel this growth during the forecast period, including the increasing burden on mental health stemming from lifestyle stress, the rising uptake of digital mental health platforms, a heightened demand for personalized treatments for depression, broadened insurance coverage for mental health services, and ongoing advancements in neuromodulation therapies. Key trends anticipated during this period encompass a greater adoption of combination therapy methods, an increasing preference for non-invasive brain stimulation treatments, enhanced awareness and diagnosis of depression, the expansion of telepsychiatry and remote mental health services, and a growing acceptance of new, fast-acting antidepressant medications.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

What Drivers Are Driving Adoption Within The Major Depressive Disorder Market?

The increasing prevalence of substance and alcohol abuse is projected to boost the major depressive disorder market. These issues, characterized by excessive and harmful use of substances, including alcohol, often lead to detrimental physical, psychological, and social effects. They frequently co-occur with major depressive disorder, with both conditions intensifying each other and significantly raising the risk of physical and mental harm. For example, a July 2024 survey from the US-based Substance Abuse and Mental Health Services Administration indicated that in 2023, 3.1% of people (8.9 million) misused opioids. It also revealed that 21.8% of individuals aged 12 or older used marijuana, making it the most commonly used illicit drug. Additionally, 9.4% of people aged 12 or older vaped nicotine in the past month, an increase from 8.3% in 2022. Thus, the escalating incidence of substance and alcohol abuse is propelling the growth of the major depressive disorder market.

How Is The Major Depressive Disorder Market Organized Into Various Segments?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5)

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) By Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) By Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) By Other Treatments: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

How Are Emerging Trends Affecting The Progression Of The Major Depressive Disorder Market?

Companies operating in the major depressive disorder (MDD) market are prioritizing the development of innovative solutions, such as prescription digital therapeutics (PDTs), to address the growing need for scalable access to evidence-based psychotherapy, adjunctive treatments for partial responders, and remote, measurement-driven care pathways. Prescription digital therapeutics (PDTs) are software-as-medical-device interventions delivered by prescription, combining clinically validated therapeutic content, remote engagement and adherence tools, and data capture for clinicians; unlike traditional antidepressant medications or in-person psychotherapy, PDTs offer repeatable, standardised, and remotely supervised behavioural interventions that can complement pharmacotherapy or bridge gaps where provider access is limited. For example, in April 2024, Otsuka Pharmaceutical Co., a pharmaceutical company based in Japan, collaborated with Click Therapeutics to launch Rejoyn (developed as CT-152). This prescription digital therapeutic was authorized by the U.S. FDA as an adjunctive treatment for adults with MDD who are concurrently taking antidepressant medication. Rejoyn is a six-week, smartphone-delivered program structured around clinically validated cognitive-emotional brain-training exercises, specifically the Emotional Faces Memory Task/EFMT, and brief therapeutic lessons designed to improve the cognitive control of emotion. The application functions through prescribed delivery; patients download and complete scheduled sessions on their smartphone while clinicians prescribe and monitor its usage. It was studied in the MIRAI randomised, sham-controlled trial, which demonstrated symptom improvement compared to the control group. Its unique features include a neuromodulatory design targeting neural networks involved in emotion processing, remote, personalized reminders to enhance adherence, and regulatory clearance as a medical device rather than a wellness app.

Who Are The Prominent Global Companies Shaping The Major Depressive Disorder Market Landscape?

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research and Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co. Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon plc, Allergan plc, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Which Region Is Projected To Lead The Major Depressive Disorder Market During The Forecast Period?

North America was the largest region in the major depressive disorder market in 2025. The regions covered in the major depressive disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Major Depressive Disorder Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13042&type=smp

Browse Through More Reports Similar to the Global Major Depressive Disorder Market 2026, By The Business Research Company

Panic Disorders Market Report 2026

https://www.thebusinessresearchcompany.com/report/panic-disorders-global-market-report

Generalized Anxiety Disorder Market Report 2026

https://www.thebusinessresearchcompany.com/report/generalized-anxiety-disorder-global-market-report

Antidepressant Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidepressant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795